Anlotinib Not Yet Recruiting Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04438902Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
NCT04211896Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
NCT03728374Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
NCT03654027Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
NCT03672136Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients